The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Appendix D Workshop Agenda
NATIONAL ACADEMY OF SCIENCES INSTITUTE OF MEDICINE
FORUM ON EMERGING INFECTIONS
"Antimicrobial Resistance, Surveillance, and Response"
2101 Constitution Avenue, N.W., Washington, D.C.
July 30-31, 1997
WEDNESDAY, July 30th
9:00
WELCOME AND INTRODUCTION
Joshua Lederberg, Forum Chairman
9:15
WHY ARE WE HERE? A FIRST LOOK AT THE COSTS OF ANTIMICROBIAL RESISTANCE
Robert Rubin, The Lewin Group
9:30
TRACKING THE PROBLEM: APPROACHES TO SURVEILLANCE AND WHAT IS NEEDED
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole. Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 112
Appendix D
Workshop Agenda
NATIONAL ACADEMY OF SCIENCES INSTITUTE OF MEDICINE
FORUM ON EMERGING INFECTIONS
"Antimicrobial Resistance, Surveillance, and Response"
2101 Constitution Avenue, N.W., Washington, D.C.
July 30-31, 1997
WEDNESDAY, July 30th
9:00
WELCOME AND INTRODUCTION
Joshua Lederberg, Forum Chairman
9:15
WHY ARE WE HERE? A FIRST LOOK AT THE COSTS OF ANTIMICROBIAL RESISTANCE
Robert Rubin, The Lewin Group
9:30
TRACKING THE PROBLEM: APPROACHES TO SURVEILLANCE AND WHAT IS NEEDED
An Overview
David Bell, CDC
The Global Perspective
David Heymann, WHO
A National Model
Donald Low, Canada
A Network for Research
Karl Kristinsson, CEM/NET
A U.S. State Perspective
Michael Osterholm, Minnesota Department of Health
OCR for page 113
10 45
INTEGRATING PRIVATE- AND PUBLIC-SECTOR SURVEILLANCE: WHAT IS HAPPENING AND WHAT IS NEEDED
Rosamund Williams, WHO
Renu Gupta, Bristol-Myers Squibb
Laurence McCarthy, MRL Pharmaceutical Services
11:30
SURVEILLANCE AND THE LABORATORY: WHAT ARE THE ISSUES?
Fred Tenover, CDC
11:45
HOW CAN THE SCIENCE HELP?
Implications of Mapping the Genome
Craig Venter, Institute for Genomic Research
Molecular Detection of Genes Associated with Antimicrobial Resistance
David Relman, Stanford University
12:30
LUNCH
1:30
HOW CAN THE SCIENCE HELP? (continued)
High-Density Oligonucleotide Arrays
Tom Gingeras, Affymetrix
Applications of Genomics/Bioinformatics to Development of Anti-Infectives
George Miller, Schering-Plough Research Institute
A Role for New Therapeutic Approaches in Combating Antimicrobial Resistance
Mich Hein, EPIcyte
Applications of Field Surveillance (U.S. and International)
Thomas Quinn, Johns Hopkins University
2:30
SOURCES OF RESISTANCE AND NOTIONS OF RESPONSE
Stuart Levy, Tufts University
2:45
ISSUES OF JUDICIOUS ANTIBIOTIC USE
Mitchell Cohen, CDC
3:00
ISSUES IN AND STRATEGIES FOR CLINICAL USE OF ANTIMICROBIALS
Michael Marcy, Kaiser Permanente
OCR for page 114
3:15
BREAK
3:30
RESISTANCE AND FOOD PRODUCTION: WHAT ISSUES, WHAT NEEDS?
Concerns and Perspectives from Producers
Paul Sundberg, National Pork Producers Council
Salmonella DT104 on the Farm
John Gay, Washington State University
Concerns and Perspectives from the U.S. Department of Agriculture
Bob Buchanan, USDA/ARS/ERRC
Kaye Wachsmuth, USDA/FSI
Concerns and Perspectives from the U.S. Environmental Protection Agency
Mark Wilhite, EPA
4:45
DISCUSSION
5:30
ADJOURN
THURSDAY, JULY 31
8:30
OTHER CONCERNS AND MECHANISMS OF RESPONSE
Legal Issues Arising from Development of Antimicrobial Resistance
David Fidler, University of Indiana
Expired Patents and the Potential of Existing Compounds*
Discussants:
Gerald Mossinghoff, George Washington School of Law
Vincent Ahonkhai, SmithKline Beecham
Restricted Distribution and the Market**
General Discussion with FDA participants as resources
*
Incentives: Developing Technologies for Emerging Infections." They were sufficiently provocative for us to feel that they merited further discussion to see what, if any, potential they might hold for stimulating new R&D and, in particular, dealing with antimicrobial resistance.
**
Please note that although the FDA is formally listed only here, several FDA experts in specific fields were present to comment and answer questions.
OCR for page 115
Orphan Drug Act Update: Looking Through the Prism of Staphylococcus aureus in Japan*
Discussants:
Fred Tenover, CDC
Mark Goldberger, FDA
10:00
GENERAL DISCUSSION: REVISITING YESTERDAY'S TOPICS AND EXTRACTING
TAKEAWAY LESSONS, ISSUES, AND NEXT STEPS
11:00
ADJOURNMENT
Items in cart [0]
